+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new day dawns: women without oestrogen or is a balance best?



A new day dawns: women without oestrogen or is a balance best?



Breast Cancer Research 4(6): 218-221



Building on the 30-year success story with tamoxifen, the question now is whether one agent can be used for treatment and prevention or should new medicines be targeted to specific applications? The early results with anastrozole suggest it could replace tamoxifen for treatment and should be tested as a preventive. Unfortunately, long-term testing of aromatase inhibitors will be required to avoid concerns about osteoporosis, Alzheimer's disease and coronary heart disease. Most importantly, the knowledge gained with tamoxifen has resulted in a new generation of selective oestrogen receptor modulators that can be used to prevent osteoporosis, breast cancer and uterine cancer. It is now clear that strategies utilising aromatase inhibitors and selective oestrogen receptor modulators will provide much needed options for individualised treatments.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045079800

Download citation: RISBibTeXText

PMID: 12473166

DOI: 10.1186/bcr538


Related references

Comparison of muscle strength and balance in post-menopausal women between those on HRT and those who were oestrogen deplete. Journal of Physiology (Cambridge) 506P: 119P-120P, 1998

Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. Journal of the Royal Society of Medicine 72(5): 322-327, 1979

Oestrogen and the cholinergic hypothesis: implications for oestrogen replacement therapy in postmenopausal women. Novartis Foundation Symposium 230: 94-107; Discussion 107-11, 2000

Oestradiol: the predominant intranuclear oestrogen in the endometrium of oestrogen-treated postmenopausal women. British Journal of Obstetrics and Gynaecology 88(9): 914-918, 1981

Changes in circulating oestrogen influence osteocyte oestrogen receptor synthesis in women. Bone (New York) 20(4 SUPPL ): 17S, 1997

Commentary: hazards of studying women: the oestrogen oestrogen/progesterone dilemma. International Journal of Epidemiology 33(3): 459-460, 2004

Effects of oestrogen and oestrogen-gestagen combination on fibrinogen and plasma viscosity in postmenopausal women. European Heart Journal 18(ABSTR SUPPL ): 557, 1997

Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation 52(4): 283-287, 1992

Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. British Medical Journal 312(7029): 473-478, 1996

Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clinical Endocrinology 58(1): 30-35, 2003

Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clinical Endocrinology 52(5): 581-585, 2000

Oestrogen receptor genotype and response of bone-health indices to dietary phyto-oestrogen intervention in European post-menopausal women. 2007